Adiponectin may play a crucial role in the metabolic effects of GLP-1RAs treatment in patients with Type 2 Diabetes Mellitus: a preliminary longitudinal study.

Al Refaie A, Baldassini L, Mondillo C, Ceccarelli E, Tarquini R, Gennari L, Gonnelli S, Caffarelli C

Endocrine9 Nov 2024Cited by 12 (Europe PMC)

PMID39521749DOI10.1007/s12020-024-04085-8PepBankPUB-39521749

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study14

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone14

In this study, the peptide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking the peptide.

01HumanNot a test of Dulaglutide (Trulicity) aloneObservational studyEfficacy outcome
In patients with T2DM, pooled dulaglutide and semaglutide treatment was linked to weight loss versus baseline.
In plain wordsIn patients with diabetes, pooled dulaglutide and semaglutide treatment was linked to lower weight than baseline.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseBody weight
Study
n = 54
Comparator
Baseline
Outcome group
Body weight · Metabolic and weight
Source sentences
Summary
In our study population, GLP-1RAs resulted in several positive changes beyond the observed weight loss:
1 context sentence(design, population, supporting numbers)
Summary · context
Fifty-four T2DM patients successfully completed the 12-month study period, with 30 receiving dulaglutide and 24 receiving semaglutide.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-3952174901
02HumanNot a test of Semaglutide aloneObservational studyEfficacy outcome
In patients with T2DM, pooled dulaglutide and semaglutide treatment was linked to weight loss versus baseline.
In plain wordsIn patients with diabetes, pooled dulaglutide and semaglutide treatment was linked to lower weight than baseline.
Peptide
Semaglutide
Outcome
DecreaseBody weight
Study
n = 54
Comparator
Baseline
Outcome group
Body weight · Metabolic and weight
Source sentences
Summary
In our study population, GLP-1RAs resulted in several positive changes beyond the observed weight loss:
1 context sentence(design, population, supporting numbers)
Summary · context
Fifty-four T2DM patients successfully completed the 12-month study period, with 30 receiving dulaglutide and 24 receiving semaglutide.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-3952174902
03HumanNot a test of Dulaglutide (Trulicity) aloneObservational studyEfficacy outcome
In patients with T2DM, pooled dulaglutide and semaglutide treatment was linked to reduced visceral fat percentage versus baseline.
In plain wordsIn patients with diabetes, pooled dulaglutide and semaglutide treatment was linked to less visceral fat than baseline.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseVisceral fat percentage
Study
n = 54
Comparator
Baseline
Outcome group
Body weight · Metabolic and weight
Measurements
Visceral fat
1.21%
before
Visceral fat
1.17%
after
Source sentences
Summary
a shift in fat distribution, indicated by a reduction in the percentage of visceral fat (1.21 vs. 1.17, p < 0.05);
1 context sentence(design, population, supporting numbers)
Summary · context
Fifty-four T2DM patients successfully completed the 12-month study period, with 30 receiving dulaglutide and 24 receiving semaglutide.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-3952174903
04HumanNot a test of Semaglutide aloneObservational studyEfficacy outcome
In patients with T2DM, pooled dulaglutide and semaglutide treatment was linked to reduced visceral fat percentage versus baseline.
In plain wordsIn patients with diabetes, pooled dulaglutide and semaglutide treatment was linked to less visceral fat than baseline.
Peptide
Semaglutide
Outcome
DecreaseVisceral fat percentage
Study
n = 54
Comparator
Baseline
Outcome group
Body weight · Metabolic and weight
Measurements
Visceral fat
1.21%
before
Visceral fat
1.17%
after
Source sentences
Summary
a shift in fat distribution, indicated by a reduction in the percentage of visceral fat (1.21 vs. 1.17, p < 0.05);
1 context sentence(design, population, supporting numbers)
Summary · context
Fifty-four T2DM patients successfully completed the 12-month study period, with 30 receiving dulaglutide and 24 receiving semaglutide.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-3952174904
05HumanNot a test of Dulaglutide (Trulicity) aloneObservational studyEfficacy outcome
In patients with T2DM, pooled dulaglutide and semaglutide treatment was linked to lower LDL cholesterol versus baseline.
In plain wordsIn patients with diabetes, pooled dulaglutide and semaglutide treatment was linked to lower LDL cholesterol than baseline.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseLDL cholesterol
Study
n = 54
Comparator
Baseline
Outcome group
Lipids · Metabolic and weight
Source sentences
Summary
a significant decrease in LDL cholesterol levels (p < 0.05) and triglycerides (p < 0.01);
1 context sentence(design, population, supporting numbers)
Summary · context
Fifty-four T2DM patients successfully completed the 12-month study period, with 30 receiving dulaglutide and 24 receiving semaglutide.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-3952174905
06HumanNot a test of Semaglutide aloneObservational studyEfficacy outcome
In patients with T2DM, pooled dulaglutide and semaglutide treatment was linked to lower LDL cholesterol versus baseline.
In plain wordsIn patients with diabetes, pooled dulaglutide and semaglutide treatment was linked to lower LDL cholesterol than baseline.
Peptide
Semaglutide
Outcome
DecreaseLDL cholesterol
Study
n = 54
Comparator
Baseline
Outcome group
Lipids · Metabolic and weight
Source sentences
Summary
a significant decrease in LDL cholesterol levels (p < 0.05) and triglycerides (p < 0.01);
1 context sentence(design, population, supporting numbers)
Summary · context
Fifty-four T2DM patients successfully completed the 12-month study period, with 30 receiving dulaglutide and 24 receiving semaglutide.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-3952174906
07HumanNot a test of Dulaglutide (Trulicity) aloneObservational studyEfficacy outcome
In patients with T2DM, pooled dulaglutide and semaglutide treatment was linked to lower triglycerides versus baseline.
In plain wordsIn patients with diabetes, pooled dulaglutide and semaglutide treatment was linked to lower triglycerides than baseline.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseTriglycerides
Study
n = 54
Comparator
Baseline
Outcome group
Lipids · Metabolic and weight
Source sentences
Summary
a significant decrease in LDL cholesterol levels (p < 0.05) and triglycerides (p < 0.01);
1 context sentence(design, population, supporting numbers)
Summary · context
Fifty-four T2DM patients successfully completed the 12-month study period, with 30 receiving dulaglutide and 24 receiving semaglutide.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-3952174907
08HumanNot a test of Semaglutide aloneObservational studyEfficacy outcome
In patients with T2DM, pooled dulaglutide and semaglutide treatment was linked to lower triglycerides versus baseline.
In plain wordsIn patients with diabetes, pooled dulaglutide and semaglutide treatment was linked to lower triglycerides than baseline.
Peptide
Semaglutide
Outcome
DecreaseTriglycerides
Study
n = 54
Comparator
Baseline
Outcome group
Lipids · Metabolic and weight
Source sentences
Summary
a significant decrease in LDL cholesterol levels (p < 0.05) and triglycerides (p < 0.01);
1 context sentence(design, population, supporting numbers)
Summary · context
Fifty-four T2DM patients successfully completed the 12-month study period, with 30 receiving dulaglutide and 24 receiving semaglutide.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-3952174908
09HumanNot a test of Dulaglutide (Trulicity) aloneObservational studyEfficacy outcome
In patients with T2DM, pooled dulaglutide and semaglutide treatment was linked to increased serum adiponectin versus baseline.
In plain wordsIn patients with diabetes, pooled dulaglutide and semaglutide treatment was linked to higher adiponectin than baseline.
Peptide
Dulaglutide (Trulicity)
Outcome
IncreaseSerum adiponectin
Study
n = 54
Comparator
Baseline
Outcome group
Inflammation markers · Endocrine and hormones
Source sentences
Summary
and a significant increase in serum adiponectin levels (p < 0.05),
1 context sentence(design, population, supporting numbers)
Summary · context
Fifty-four T2DM patients successfully completed the 12-month study period, with 30 receiving dulaglutide and 24 receiving semaglutide.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-3952174909
10HumanNot a test of Semaglutide aloneObservational studyEfficacy outcome
In patients with T2DM, pooled dulaglutide and semaglutide treatment was linked to increased serum adiponectin versus baseline.
In plain wordsIn patients with diabetes, pooled dulaglutide and semaglutide treatment was linked to higher adiponectin than baseline.
Peptide
Semaglutide
Outcome
IncreaseSerum adiponectin
Study
n = 54
Comparator
Baseline
Outcome group
Inflammation markers · Endocrine and hormones
Source sentences
Summary
and a significant increase in serum adiponectin levels (p < 0.05),
1 context sentence(design, population, supporting numbers)
Summary · context
Fifty-four T2DM patients successfully completed the 12-month study period, with 30 receiving dulaglutide and 24 receiving semaglutide.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-3952174910
11HumanNot a test of Dulaglutide (Trulicity) aloneObservational studyEfficacy outcome
In patients with T2DM, pooled dulaglutide and semaglutide treatment was linked to decreased microalbuminuria versus baseline.
In plain wordsIn patients with diabetes, pooled dulaglutide and semaglutide treatment was linked to less urine albumin than baseline.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseMicroalbuminuria
Study
n = 54
Comparator
Baseline
Outcome group
Kidney function · Kidney and urinary
Source sentences
Summary
Additionally, we observed a significant decrease in microalbuminuria and media-intimal thickness at the carotid vessel level (p < 0.05).
1 context sentence(design, population, supporting numbers)
Summary · context
Fifty-four T2DM patients successfully completed the 12-month study period, with 30 receiving dulaglutide and 24 receiving semaglutide.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-3952174911
12HumanNot a test of Semaglutide aloneObservational studyEfficacy outcome
In patients with T2DM, pooled dulaglutide and semaglutide treatment was linked to decreased microalbuminuria versus baseline.
In plain wordsIn patients with diabetes, pooled dulaglutide and semaglutide treatment was linked to less urine albumin than baseline.
Peptide
Semaglutide
Outcome
DecreaseMicroalbuminuria
Study
n = 54
Comparator
Baseline
Outcome group
Kidney function · Kidney and urinary
Source sentences
Summary
Additionally, we observed a significant decrease in microalbuminuria and media-intimal thickness at the carotid vessel level (p < 0.05).
1 context sentence(design, population, supporting numbers)
Summary · context
Fifty-four T2DM patients successfully completed the 12-month study period, with 30 receiving dulaglutide and 24 receiving semaglutide.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-3952174912
13HumanNot a test of Dulaglutide (Trulicity) aloneObservational studyEfficacy outcome
In patients with T2DM, pooled dulaglutide and semaglutide treatment was linked to decreased carotid media-intimal thickness versus baseline.
In plain wordsIn patients with diabetes, pooled dulaglutide and semaglutide treatment was linked to thinner carotid vessel walls than baseline.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseCarotid media-intimal thickness
Study
n = 54
Comparator
Baseline
Outcome group
Vascular function · Cardiovascular
Source sentences
Summary
Additionally, we observed a significant decrease in microalbuminuria and media-intimal thickness at the carotid vessel level (p < 0.05).
1 context sentence(design, population, supporting numbers)
Summary · context
Fifty-four T2DM patients successfully completed the 12-month study period, with 30 receiving dulaglutide and 24 receiving semaglutide.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-3952174913
14HumanNot a test of Semaglutide aloneObservational studyEfficacy outcome
In patients with T2DM, pooled dulaglutide and semaglutide treatment was linked to decreased carotid media-intimal thickness versus baseline.
In plain wordsIn patients with diabetes, pooled dulaglutide and semaglutide treatment was linked to thinner carotid vessel walls than baseline.
Peptide
Semaglutide
Outcome
DecreaseCarotid media-intimal thickness
Study
n = 54
Comparator
Baseline
Outcome group
Vascular function · Cardiovascular
Source sentences
Summary
Additionally, we observed a significant decrease in microalbuminuria and media-intimal thickness at the carotid vessel level (p < 0.05).
1 context sentence(design, population, supporting numbers)
Summary · context
Fifty-four T2DM patients successfully completed the 12-month study period, with 30 receiving dulaglutide and 24 receiving semaglutide.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-3952174914

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 3Current
22 Oct 2026, 02:25 UTC
Study results updated
Version 2
21 Oct 2026, 18:59 UTC
Study data updated · source update from Europe PMC
Version 1
9 Oct 2026, 03:06 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.